{"filing":{"accession_number":"0001683168-26-007300","cik":"0001787740","ticker":"VBIO","company_name":"Valion Bio, Inc.","form":"8-K","filing_date":"2026-09-23","report_date":"2026-09-17","primary_document":"valion_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1787740/000168316826007300/valion_8k.htm"},"events":[{"id":34480,"run_id":31727,"accession_number":"0001683168-26-007300","anchor_item_number":"5.02","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.94,"summary":"Dean Zikria, a current board member, was appointed as Interim Chief Executive Officer of Valion Bio effective September 22, 2026. The appointment also includes compensatory arrangements (monthly fee of $23,333, 50,000 RSUs, and potential bonus) and is accompanied by related board leadership transitions including Thomas Jensen's appointment as Board Chair and Sheryle Bolton's resignation.","company_name":"Valion Bio, Inc.","ticker":"VBIO","filing_date":"2026-09-23","form":"8-K","submitted_at":null,"items":[{"id":38210,"accession_number":"0001683168-26-007300","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"Dean Zikria was appointed as Interim Chief Executive Officer of Valion Bio effective September 22, 2026. While the filing also discloses compensatory arrangements (monthly fee of $23,333, 50,000 RSUs, and potential bonus), the principal disclosed action is the appointment of Zikria to the CEO role. The appointment of a new CEO is material to investors as it represents a significant leadership change at a clinical-stage biopharmaceutical company. The filing also includes related board transitions (Thomas Jensen as Board Chair, Jared Malbin as Audit Committee Chair, and Sheryle Bolton's resignation), but the CEO appointment is the primary event.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-23T12:02:48.015158+00:00","company_name":"","ticker":null,"filing_date":""},{"id":38211,"accession_number":"0001683168-26-007300","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"The filing announces the appointment of Dean Zikria, a current board member, as Interim CEO of Valion Bio. While the press release also mentions board leadership transitions (Thomas Jensen appointed Board Chair, Sheryle Bolton stepping down), the principal disclosed action centers on the executive appointment of a new CEO. The appointment is material as it represents a significant change in executive leadership at a clinical-stage biopharmaceutical company during an important development phase.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-23T12:02:48.015158+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":38210,"accession_number":"0001683168-26-007300","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"Dean Zikria was appointed as Interim Chief Executive Officer of Valion Bio effective September 22, 2026. While the filing also discloses compensatory arrangements (monthly fee of $23,333, 50,000 RSUs, and potential bonus), the principal disclosed action is the appointment of Zikria to the CEO role. The appointment of a new CEO is material to investors as it represents a significant leadership change at a clinical-stage biopharmaceutical company. The filing also includes related board transitions (Thomas Jensen as Board Chair, Jared Malbin as Audit Committee Chair, and Sheryle Bolton's resignation), but the CEO appointment is the primary event.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-23T12:02:48.015158+00:00","company_name":"Valion Bio, Inc.","ticker":"VBIO","filing_date":"2026-09-23"},{"id":38211,"accession_number":"0001683168-26-007300","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"The filing announces the appointment of Dean Zikria, a current board member, as Interim CEO of Valion Bio. While the press release also mentions board leadership transitions (Thomas Jensen appointed Board Chair, Sheryle Bolton stepping down), the principal disclosed action centers on the executive appointment of a new CEO. The appointment is material as it represents a significant change in executive leadership at a clinical-stage biopharmaceutical company during an important development phase.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-23T12:02:48.015158+00:00","company_name":"Valion Bio, Inc.","ticker":"VBIO","filing_date":"2026-09-23"}]}